A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice
Yang Yang(The University of Texas at San Antonio Health Science Center), Daohong Zhou(The University of Texas at San Antonio Health Science Center)
Cited by 37
Related Papers
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
|Nature Communications|2021|145
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
|Journal of Hematology & Oncology|2020|129